Khalid Shah

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5016547/publications.pdf

Version: 2024-02-01

98 papers	6,093 citations	94381 37 h-index	74108 75 g-index
121 all docs	121 docs citations	121 times ranked	7619 citing authors

#	Article	IF	Citations
1	Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells, 2022, 11, 465.	1.8	3
2	NK cells in the brain: implications for brain tumor development and therapy. Trends in Molecular Medicine, 2022, 28, 194-209.	3.5	10
3	Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors. Journal of Clinical Investigation, 2022, 132, .	3.9	28
4	Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. EBioMedicine, 2022, 77, 103908.	2.7	80
5	The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm. JAMA Oncology, 2022, 8, 1059.	3.4	29
6	Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. Nature Communications, 2022, 13, 2810.	5.8	10
7	Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188458.	3.3	34
8	Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clinical Cancer Research, 2021, 27, 889-902.	3.2	41
9	Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery. Nano Today, 2021, 36, 101045.	6.2	24
10	Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies. Cells, 2021, 10, 491.	1.8	5
11	Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. Oncogene, 2021, 40, 3201-3216.	2.6	5
12	Anti-EGFR VHH-armed death receptor ligandâ€“engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. Science Advances, 2021, 7, .	4.7	10
13	IL13RÎ±2â€˜ and EGFRâ€˜targeted pseudomonas exotoxin potentiates the TRAILâ€˜mediated death of GBM cells. International Journal of Molecular Medicine, 2021, 48, .	1.8	5
14	Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells, 2021, 10, 1541.	1.8	24
15	Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. Molecular Therapy - Oncolytics, 2021, 21, 377-388.	2.0	12
16	Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?. Frontiers in Oncology, 2021, 11, 678562.	1.3	15
17	OMRT-14. Small molecule circadian clock compounds exhibit potential as a novel therapy paradigm for glioblastoma. Neuro-Oncology Advances, 2021, 3, ii9-ii9.	0.4	0
18	OTHR-02. Engineered â€œof the shelfâ€•allogeneic cellular therapies for metastatic brain tumors. Neuro-Oncology Advances, 2021, 3, iii14-iii14.	0.4	0

#	Article	IF	Citations
19	Next-generation immunotherapies for brain metastatic cancers. Trends in Cancer, 2021, 7, 809-822.	3.8	6
20	BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma. Journal of Biological Chemistry, 2021, 297, 101223.	1.6	3
21	Immunotherapy in hematological malignancies: recent advances and open questions. Immunotherapy, 2021, 13, 1215-1229.	1.0	11
22	Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells, 2021, 39, 707-722.	1.4	42
23	Modulating microRNAs in cancer: Next-generation therapies. Cancer Biology and Medicine, 2021, , 1-1.	1.4	9
24	Engineered stem cells targeting multiple cell surface receptors in tumors. Stem Cells, 2020, 38, 34-44.	1.4	7
25	Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. Cell, 2020, 183, 1219-1233.e18.	13.5	54
26	Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. Nature Communications, 2020, 11, 3912.	5.8	81
27	Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends in Pharmacological Sciences, 2020, 41, 653-664.	4.0	379
28	Shattering barriers toward clinically meaningful MSC therapies. Science Advances, 2020, 6, eaba6884.	4.7	351
29	TRAIL of Hope Meeting Resistance in Cancer. Trends in Cancer, 2020, 6, 989-1001.	3.8	70
30	Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Frontiers in Oncology, 2020, 10, 1182.	1.3	167
31	Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1751-1764.	1.2	11
32	Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. PLoS ONE, 2020, 15, e0228510.	1.1	4
33	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Molecular Cell, 2020, 78, 1207-1223.e8.	4.5	43
34	Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy. Scientific Reports, 2020, 10, 1779.	1.6	29
35	Tartary buckwheat extract alleviates alcohol-induced acute and chronic liver injuries through the inhibition of oxidative stress and mitochondrial cell death pathway. American Journal of Translational Research (discontinued), 2020, 12, 70-89.	0.0	5
36	TMOD-01. DEVELOPING CLINICALLY RELEVANT BRAIN METASTATIC TUMOR MODELS FOR TARGETED STEM CELL THERAPEUTICS. Neuro-Oncology, 2020, 22, ii227-ii227.	0.6	0

#	Article	IF	Citations
37	Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. , 2020, 15, e0228510.		0
38	Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. , 2020, 15, e0228510.		0
39	Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. , 2020, 15, e0228510.		0
40	Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. , 2020, 15, e0228510.		0
41	EXTH-49. THERAPEUTIC EFFICACY OF ENGINEERED, HYDROGEL ENCAPSULATED BIMODAL MSC IN GLIOBLASTOMA STRATIFIED ON CELL SURFACE RECEPTOR EXPRESSION. Neuro-Oncology, 2019, 21, vi93-vi93.	0.6	0
42	TMIC-25. MODIFICATION OF EXTRACELLULAR MATRIX ENHANCES ONCOLYTIC ADENOVIRUS IMMUNOTHERAPY IN GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi252-vi253.	0.6	0
43	A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging. Cancer Gene Therapy, 2019, 26, 145-156.	2.2	5
44	Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Scientific Reports, 2019, 9, 139.	1.6	9
45	Stem Cells Engineered During Different Stages of Reprogramming Reveal Varying Therapeutic Efficacies. Stem Cells, 2018, 36, 932-942.	1.4	7
46	microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. Neuro-Oncology, 2018, 20, 215-224.	0.6	32
47	STEM-02. DEVELOPING BRAIN METASTATIC TUMOR MODELS FOR TARGETED STEM CELL THERAPY. Neuro-Oncology, 2018, 20, vi243-vi244.	0.6	0
48	Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions. Theranostics, 2018, 8, 3380-3391.	4.6	11
49	CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors. Science Translational Medicine, 2018, 10, .	5.8	39
50	Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. International Journal of Cancer, 2017, 141, 1671-1681.	2.3	26
51	TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2017, 7, 1336-1353.	7.7	48
52	Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNÎ² in Glioblastomas. Clinical Cancer Research, 2017, 23, 7047-7058.	3.2	36
53	Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Scientific Reports, 2017, 7, 2602.	1.6	40
54	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6157-E6165.	3.3	90

#	Article	IF	Citations
55	SCDT-26. STEM CELL LOADED ONCOLYTIC VIRUSES TRACK AND KILL METASTATIC BRAIN TUMORS. Neuro-Oncology, 2017, 19, vi270-vi270.	0.6	0
56	Stem cell-based therapies for tumors in the brain: are we there yet?. Neuro-Oncology, 2016, 18, 1066-1078.	0.6	52
57	Engineered bifunctional proteins and stem cells: next generation of targeted cancer therapeutics. Discovery Medicine, 2016, 22, 157-166.	0.5	3
58	Stem Cell-Based Therapies for Cancer. Advances in Cancer Research, 2015, 127, 159-189.	1.9	11
59	Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain, 2015, 138, 1710-1721.	3.7	38
60	Multifunctional receptor-targeting antibodies for cancer therapy. Lancet Oncology, The, 2015, 16, e543-e554.	5.1	36
61	Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas. Molecular Therapy, 2015, 23, 235-243.	3.7	44
62	Encapsulated Stem Cells Loaded With Hyaluronidase-expressing Oncolytic Virus for Brain Tumor Therapy. Molecular Therapy, 2015, 23, 108-118.	3.7	97
63	Combination of Systemic Chemotherapy with Local Stem Cell Delivered S-TRAIL in Resected Brain Tumors. Stem Cells, 2015, 33, 101-110.	1.4	34
64	PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 379-89.	1.0	10
65	Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. Cancer Biology and Therapy, 2014, 15, 815-822.	1.5	35
66	AEG-1 Regulates Retinoid X Receptor and Inhibits Retinoid Signaling. Cancer Research, 2014, 74, 4364-4377.	0.4	39
67	Response. Journal of the National Cancer Institute, 2014, 107, dju370-dju370.	3.0	1
68	Stem Cells Loaded With Multimechanistic Oncolytic Herpes Simplex Virus Variants for Brain Tumor Therapy. Journal of the National Cancer Institute, 2014, 106, dju090.	3.0	102
69	Stem cell-based therapies for cancer treatment: separating hope from hype. Nature Reviews Cancer, 2014, 14, 683-691.	12.8	190
70	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. Cancer Discovery, 2014, 4, 1299-1309.	7.7	207
71	Molecular Imaging with Bioluminescence and PET Reveals Viral Oncolysis Kinetics and Tumor Viability. Cancer Research, 2014, 74, 4111-4121.	0.4	11
72	Targeting c-Met Receptor Overcomes TRAIL-Resistance in Brain Tumors. PLoS ONE, 2014, 9, e95490.	1.1	14

#	Article	IF	Citations
73	TRAIL on trial: preclinical advances in cancer therapy. Trends in Molecular Medicine, 2013, 19, 685-694.	3.5	243
74	Multimechanistic Tumor Targeted Oncolytic Virus Overcomes Resistance in Brain Tumors. Molecular Therapy, 2013, 21, 68-77.	3.7	46
75	Encapsulated stem cells for cancer therapy. Biomatter, 2013, 3, .	2.6	42
76	Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors. Stem Cells, 2013, 31, 1706-1714.	1.4	89
77	Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16642-16647.	3.3	70
78	Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nature Neuroscience, 2012, 15, 197-204.	7.1	194
79	Mesenchymal stem cells engineered for cancer therapy. Advanced Drug Delivery Reviews, 2012, 64, 739-748.	6.6	285
80	A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cellâ€“Delivered TRAIL in Experimental Glioma Models. Cancer Research, 2011, 71, 154-163.	0.4	94
81	Imaging Fate of Stem Cells at a Cellular Resolution in the Brains of Mice. Methods in Molecular Biology, 2011, 680, 91-101.	0.4	1
82	In Vivo Imaging of the Dynamics of Different Variants of EGFR in Glioblastomas. Methods in Molecular Biology, 2011, 680, 153-164.	0.4	1
83	A Novel Molecule Integrating Therapeutic and Diagnostic Activities Reveals Multiple Aspects of Stem Cell-based Therapy. Stem Cells, 2010, 28, 832-841.	1.4	54
84	Human Glioblastomaâ€“Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors. Cancer Research, 2009, 69, 3472-3481.	0.4	303
85	Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4822-4827.	3.3	425
86	Imaging Neural Stem Cell Fate in Mouse Model of Glioma. , 2009, Chapter 5, Unit 5A.1.		9
87	Bimodal Viral Vectors andIn VivoImaging Reveal the Fate of Human Neural Stem Cells in Experimental Glioma Model. Journal of Neuroscience, 2008, 28, 4406-4413.	1.7	98
88	MicroRNA-21 Knockdown Disrupts Glioma Growth In vivo and Displays Synergistic Cytotoxicity with Neural Precursor Cellâ€“Delivered S-TRAIL in Human Gliomas. Cancer Research, 2007, 67, 8994-9000.	0.4	416
89	Tumor Therapy Mediated by Lentiviral Expression of shBcl-2 and S-TRAIL. Neoplasia, 2007, 9, 435-442.	2.3	71
90	HSV Amplicon Vectors for Cancer Therapy. Current Gene Therapy, 2006, 6, 361-370.	0.9	19

#	ARTICLE	IF	CITATIONS
91	Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals of Neurology, 2005, 57, 34-41.	2.8	188
92	In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Molecular Therapy, 2005, 11, 926-931.	3.7	105
93	Molecular optical imaging: Applications leading to the development of present day therapeutics. NeuroRx, 2005, 2, 215-225.	6.0	165
94	Molecular optical imaging: Applications leading to the development of present day therapeutics. Neurotherapeutics, 2005, 2, 215-225.	2.1	0
95	Inducible Release of TRAIL Fusion Proteins from a Proapoptotic Form for Tumor Therapy. Cancer Research, 2004, 64, 3236-3242.	0.4	91
96	In Vivo Imaging of HIV Protease Activity in Amplicon Vector-transduced Gliomas. Cancer Research, 2004, 64, 273-278.	0.4	51
97	Neural Precursor Cells and Their Role in Neuro-Oncology. Developmental Neuroscience, 2004, 26, 118-130.	1.0	22
98	Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene, 2003, 22, 6865-6872.	2.6	128